Effect of tamoxifen on lipids and lipid metabolising marker enzymes in experimental atherosclerosis in Wistar rats.
Tamoxifen, a non-steroidal anti-oestrogen, is used in the treatment of breast cancer, both receptor positive and negative tumours. It also possesses weak oestrogenic activity which forms the basis of this study. Tamoxifen (2 different dosages) was administered through diet (10 mg/kg diet and 20 mg/kg diet) to experimental atherosclerosis induced female rats to assess the effect of tamoxifen on plasma lipid levels, lipoprotein cholesterol level and on the activity of lipid metabolising enzymes. The plasma total lipid level was increased in atherosclerosis suffering animals compared to control animals with concomitant changes in the activity of lipid metabolising enzymes. HDL-cholesterol was decreased while LDL-cholesterol and VLDL-cholesterol were increased in the atherosclerosis induced group. Cholesterol and free cholesterol were decreased in tamoxifen treated groups while the other lipids show a moderate increase. HDL-cholesterol was increased but LDL-cholesterol was decreased in the tamoxifen treated groups. The higher dosage tamoxifen given group animals show significantly favourable results from therapy stand point when compared to diseased group.
Vinitha
R
R
Department of Medical Biochemistry Dr. A.L.M. Post-Graduate Institute of Basic Medical Sciences, University of Madras, India.
Thangaraju
M
M
Sachdanandam
P
P
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000201:enzymology*; D002784:Cholesterol / Q000097:blood; D005260:Female; D008055:Lipids / Q000097:blood*; D008071:Lipoprotein Lipase / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013629:Tamoxifen / Q000494:pharmacology* / Q000627:therapeutic use
D008055:Lipids; D013629:Tamoxifen; D002784:Cholesterol; D008071:Lipoprotein Lipase